Numinus Wellness Inc.

TSXV: NUMI, OTC: LKYSD

Company Overview

Numinus Wellness Inc. is an operating company at the forefront of addressing the growing prevalence of mental health issues and the desire for greater wellness.

The company's operations include Numinus Bioscience, a testing and research facility that can leverage the emerging market of psychedelic therapies to address mental illness, addictions and PTSD; Numinus Wellness, a treatment and healing centre model we aim to scale globally; and Numinus R&D, which is creating partnerships with leading research groups to advance practice and understanding in the space.

Sustainable cannabis revenue through Numinus Bioscience's laboratory and production operations will help fund our growth plans.

Financial Highlights

$947,969

Revenue (ttm)

$82,958

Gross Profit (ttm)

-$0.12

Diluted EPS (ttm)

Management Team

Mr. Michael Tan M.B.A.
COO & Director

Mr. Payton Nyquvest
Co-Founder, Pres, CEO & Chairman

Ms. Stacey Wallin
Co-Founder & Chief Strategy Officer

Mr. John Fong CPA, CGA
CFO & Corp. Sec.

Mr. Ian Noble
Chief Communications Officer

Dr. Evan Wood M.D., Ph.D.
Chief Medical Officer & Member of the Clinical Advisory Council

Ms. Judy Varga M.Sc.
Head of Laboratory Operations

Dr. Devon Christie M.D.
Medical Director & Member of the Clinical Advisory

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$89,132,089

Shares Outstanding
94,821,372

Shares Short (% of Float)
291,650 (0%)

Insider Ownership
6%